Full Press Release Details
REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100%
Montreal, Canada - (GLOBE NEWSWIRE) -
Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company offering and researching life-saving medicines in a variety
of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter report. The Report shows
gross revenues of $4,894,053 as of March 31, 2023, an increase of more than 2,100% over the same period in 2022. The increase was largely
due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October
The following are 2023 first quarter highlights:
"We are thrilled with our first quarter
results and look forward to equally exciting results for the rest of 2023 and further growth in the coming year and beyond," said
Camille Sebaaly, CFO of Sunshine Biopharma.
About Sunshine Biopharma
Sunshine Biopharma recently acquired Nora Pharma
Inc. and as a result the Company now has 50 generic prescription drugs on the market in Canada and 48 employees. The Company is planning
to expand its product offering to 86 generic pharmaceuticals over the next two years. In parallel, Sunshine Biopharma is continuing its
proprietary drug development program which is comprised of (i) K1.1 mRNA for liver cancer, (ii) Adva-27a, a small chemotherapy molecule
for pancreatic cancer, and (iii) PLpro inhibitor for COVID-19. For more information, please visit: www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
This press release contains forward-looking
statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company")
that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or
expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the
intent, belief or current expectations of the Company, including statements related to the Company's drug development activities,
financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with
the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those
projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's
filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent
For Additional Information:
Sunshine Biopharma Contact:
Camille Sebaaly, CFO